27 participants
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-06-25
- Start Date:
- 2020-09-14
- Completion:
- 2022-07-31
Conditions
- Hepatocellular Carcinoma
- Liver Neoplasms
- Digestive System Neoplasms
- Sorafenib
- Molecular Mechanisms of Pharmacological Action
- Liver Diseases
- Antineoplastic Agents
- Protein Kinase Inhibitors
Interventions
- COMBINATION_PRODUCT
No Results Yet